Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Diffusion Pharmaceuticals Inc (DFFN)

Diffusion Pharmaceuticals Inc (DFFN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,801
  • Shares Outstanding, K 2,039
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,100 K
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade DFFN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.77
  • Number of Estimates 2
  • High Estimate -1.50
  • Low Estimate -2.04
  • Prior Year -2.00
  • Growth Rate Est. (year over year) +11.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.53 +3.68%
on 06/30/22
8.47 -20.07%
on 06/02/22
-0.98 (-12.65%)
since 06/01/22
3-Month
5.10 +32.75%
on 04/28/22
15.36 -55.94%
on 04/12/22
-5.50 (-44.85%)
since 04/01/22
52-Week
5.10 +32.75%
on 04/28/22
38.00 -82.18%
on 07/06/21
-29.13 (-81.14%)
since 07/01/21

Most Recent Stories

More News
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.• No Change to Meeting Location, Record Date, or Proposals to Be...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO TrialPhase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia...

DFFN : 6.77 (+1.35%)
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical...

DFFN : 6.77 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. The Company is focused on cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant...

See More

Key Turning Points

3rd Resistance Point 7.22
2nd Resistance Point 7.06
1st Resistance Point 6.92
Last Price 6.77
1st Support Level 6.61
2nd Support Level 6.45
3rd Support Level 6.30

See More

52-Week High 38.00
Fibonacci 61.8% 25.43
Fibonacci 50% 21.55
Fibonacci 38.2% 17.67
Last Price 6.77
52-Week Low 5.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar